Patients with HF exhibited a higher incidence of chronic GvHD, a lower risk of measurable residual disease recurrence, and improved event-free survival, particularly among those receiving ATG-based acute GvHD prophylaxis. Using multiple complementary approaches, the authors demonstrated the impact of HF on transplant outcomes, identified its risk factors, and elucidated the underlying cellular and molecular mechanisms.
Countstar Connection
Cell concentration and viability were measured in the study's cell samples with Countstar (model not specified) during quality assessment in the 2026 Blood science study.
